|
US3254124A
(en)
|
1962-06-29 |
1966-05-31 |
Parke Davis & Co |
Aminoketones and methods for their production
|
|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
US4670459A
(en)
|
1984-10-03 |
1987-06-02 |
Merrell Dow Pharmaceuticals Inc. |
Method of alleviating withdrawal symptoms
|
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
|
DE19619665C2
(de)
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemattrennung von Ketamin
|
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
|
US6382204B1
(en)
|
1999-10-14 |
2002-05-07 |
Becton Dickinson And Company |
Drug delivery system including holder and drug container
|
|
US6962151B1
(en)
|
1999-11-05 |
2005-11-08 |
Pari GmbH Spezialisten für effektive Inhalation |
Inhalation nebulizer
|
|
DE60134459D1
(de)
|
2000-02-23 |
2008-07-31 |
Amgen Inc |
Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
|
|
BRPI0002693B8
(pt)
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
EP1551393A4
(en)
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
JP2006510618A
(ja)
|
2002-11-18 |
2006-03-30 |
ヤウポン セラピューティクス，インコーポレーテッド |
ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
|
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
US7928132B2
(en)
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
|
CN101309667A
(zh)
|
2005-09-28 |
2008-11-19 |
奥里斯医学股份有限公司 |
治疗内耳疾病的药用合成物
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
BRPI0809843A2
(pt)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US20110038807A1
(en)
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20140057988A1
(en)
|
2012-08-23 |
2014-02-27 |
Stuart WEG |
Anxiolytic composition, formulation and method of use
|
|
NZ712270A
(en)
|
2013-03-15 |
2020-02-28 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
AU2014240102A1
(en)
|
2013-03-15 |
2015-09-17 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of S-ketamine hydrochloride
|
|
MX370506B
(es)
|
2013-04-12 |
2019-12-16 |
Icahn School Med Mount Sinai |
Método para tratar trastorno de estrés post-traumático.
|
|
US9872841B2
(en)
|
2013-09-13 |
2018-01-23 |
National University Corporation Chiba University |
Application of R-ketamine and salt thereof as pharmaceuticals
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
WO2015108985A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
AU2015254037B2
(en)
|
2014-04-29 |
2019-03-21 |
The Catholic University Of Korea Industry-Academic Cooperation Foundation |
Novel compound having immune disease treatment effect and use thereof
|
|
CA2957926A1
(en)
|
2014-08-13 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
AU2015318123A1
(en)
|
2014-09-15 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
CN115521217A
(zh)
|
2014-11-04 |
2022-12-27 |
阿莫萨治疗公司 |
神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20200297734A1
(en)
|
2015-06-19 |
2020-09-24 |
Melt Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for anesthesiological applications
|
|
JP6570015B2
(ja)
|
2015-06-19 |
2019-09-04 |
メルト ファーマスーティカルズ，インコーポレイテッド |
麻酔用途のための医薬組成物
|
|
CN107847469A
(zh)
|
2015-06-27 |
2018-03-27 |
美国神农制药责任有限公司 |
氯胺酮透皮递送系统
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
JP2019512528A
(ja)
|
2016-03-25 |
2019-05-16 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
|
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US11103499B2
(en)
|
2016-08-26 |
2021-08-31 |
EXCIVA (UG) (haftungsbeschränkt) |
Compositions and methods thereof
|
|
US20200261442A1
(en)
|
2016-08-26 |
2020-08-20 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
WO2018075481A1
(en)
|
2016-10-17 |
2018-04-26 |
Yale University |
Compounds, compositions and methods for treating or preventing depression and other diseases
|
|
IL315066A
(en)
|
2016-10-27 |
2024-10-01 |
Univ Chiba Nat Univ Corp |
Application of (s)-norketamine and salt therof as pharmaceutical
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
WO2018125629A1
(en)
|
2016-12-27 |
2018-07-05 |
Action Medical Technologies, Llc |
Apparatuses and method for injecting medicaments
|
|
AU2018215056A1
(en)
|
2017-01-31 |
2019-08-08 |
Charles E. Inturrisi |
D-methadone and its derivatives for use in the treatment of disorders of the nervous system
|
|
US11478467B2
(en)
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
CA3064846A1
(en)
|
2017-05-25 |
2018-11-29 |
Glytech, Llc |
Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
Hydroxynorketamine for the use in the treatment of depression
|
|
WO2019065900A1
(ja)
|
2017-09-27 |
2019-04-04 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US10869838B2
(en)
|
2017-10-10 |
2020-12-22 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
CN107823195A
(zh)
|
2017-11-24 |
2018-03-23 |
无锡市精神卫生中心 |
R‑氯胺酮在抑郁症急性期治疗中的应用
|
|
EP3505509A1
(en)
|
2017-12-29 |
2019-07-03 |
Université de Liège |
Methods for the preparation of arylcycloalkylamine derivatives
|
|
JP7167168B2
(ja)
|
2018-01-10 |
2022-11-08 |
エックスダブリューファルマ リミテッド |
ケタミンのプロドラッグ、組成物及びそれらの使用
|
|
BR112020016500A2
(pt)
|
2018-02-15 |
2020-12-15 |
National University Corporation Chiba University |
Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
|
|
WO2019169165A1
(en)
|
2018-02-28 |
2019-09-06 |
Novocine Therapeutics, Llc |
Ketamine and ketamine-related compounds for the treatment of neurological disorders
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
JP2021523228A
(ja)
|
2018-05-04 |
2021-09-02 |
パーセプション ニューロサイエンス，インコーポレイティド |
物質乱用の治療方法
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
EP3813807A1
(en)
|
2018-06-27 |
2021-05-05 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
KR20210074275A
(ko)
|
2018-10-05 |
2021-06-21 |
클렉시오 바이오사이언시스 리미티드 |
주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
|
|
US12364672B2
(en)
|
2018-10-11 |
2025-07-22 |
Clexio Biosciences Ltd. |
Esketamine for use in treating major depressive disorder
|
|
US20220110889A1
(en)
|
2018-12-27 |
2022-04-14 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
|
|
DK3908570T3
(da)
|
2019-01-11 |
2024-02-26 |
Alar Pharmaceuticals Inc |
Ketaminpamoat og andevendelse deraf
|
|
WO2020198039A1
(en)
|
2019-03-23 |
2020-10-01 |
Sermone Sandra |
Ketamine for treatment of sensory processing deficits
|
|
EP3956300A1
(en)
|
2019-04-16 |
2022-02-23 |
Janssen Pharmaceutica NV |
Synthetic methods of preparing esketamine
|
|
EP3968979A4
(en)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
|
|
AU2020324432A1
(en)
|
2019-08-05 |
2021-10-07 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
US11007200B2
(en)
|
2019-08-21 |
2021-05-18 |
MediSynergics, LLC |
Cycloalkyl-diamines for the treatment of pain
|
|
TWI862759B
(zh)
|
2019-12-20 |
2024-11-21 |
昱展新藥生技股份有限公司 |
氯胺酮雙羥萘酸鹽的長效注射劑型
|
|
JP7644122B2
(ja)
|
2019-12-26 |
2025-03-11 |
ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド |
アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
US12268658B2
(en)
|
2019-12-30 |
2025-04-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
CA3173641A1
(en)
|
2020-03-27 |
2021-09-30 |
Barbara SCOLNICK |
Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
|
|
US20230121608A1
(en)
|
2020-04-07 |
2023-04-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety- Like Behavior
|
|
US12128012B2
(en)
|
2020-05-15 |
2024-10-29 |
University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
|
WO2021252971A2
(en)
|
2020-06-12 |
2021-12-16 |
Bexson Biomedical, Inc. |
Systems and devices for controlled drug delivery
|
|
WO2021255737A1
(en)
|
2020-06-17 |
2021-12-23 |
Spirify Pharma Inc. |
Hydroxynorketamine analogues, compositions comprising same and methods of use thereof
|
|
WO2023064363A1
(en)
|
2021-10-12 |
2023-04-20 |
Perception Neuroscience, Inc. |
R-ketamine salts and methods of use thereof
|
|
CA3245931A1
(en)
|
2022-03-14 |
2023-09-21 |
Perception Neuroscience, Inc. |
R-KETAMINE PHARMACEUTICAL FORMULATIONS
|
|
US20250281426A1
(en)
|
2022-04-26 |
2025-09-11 |
Yichang Humanwell Pharmaceutical Co., Ltd. |
R-ketamine liquid preparation and use thereof
|
|
US20260027068A1
(en)
|
2022-12-28 |
2026-01-29 |
Perception Neuroscience, Inc. |
Methods of administering r-ketamine
|